No CrossRef data available.
Article contents
Caffeine and clinical change in a patient with schizophrenia on a long-stay ward
Published online by Cambridge University Press: 13 June 2014
Abstract
We report a case of a 33-year-old male patient with schizophrenia, who showed significant and persistent changes in psychotic and mood symptoms relating to his caffeine intake.
- Type
- Case Report
- Information
- Copyright
- Copyright © Cambridge University Press 2011
References
1.Sadock, B, Sadock, V. Kaplan & Sadock's Synopsis of Psychiatry: behavioral sciences/clinical psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2003.Google Scholar
2.Schneier, F, Siris, S. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. The Journal of nervous and mental disease. 1987 November; 175(11): p. 641–652.CrossRefGoogle ScholarPubMed
3.Rihs, M, Muller, C, Baumann, P. Caffeine consumption in hospitalized psychiatric patients. European archives of psychiatry and clinical neuroscience. 1996; 246(2): p. 83–92.CrossRefGoogle ScholarPubMed
4.Hughes, J, McHugh, P, Holtzman, S. Caffeine and Schizophrenia. Psychiatric Services. 1998 November; 49(11): p. 1415–1417.CrossRefGoogle ScholarPubMed
5.Broderick, P, Benjamin, A. Caffeine and psychiatric symptoms: a review. The Journal of the Oklahoma State Medical Association. 2004 December; 97(12): p. 538–542.Google ScholarPubMed
6.Taylor, D, Paton, C, Kerwin, R. The Maudsley Prescribing Guidelines. 9th ed. London: Informa Healthcare; 2007.CrossRefGoogle Scholar
7.Nehlig, A, Daval, J, Debry, G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev. 1992 May-Aug; 17(2): p. 139–170.CrossRefGoogle ScholarPubMed
8.Stoner, G, Skirball, L, Werhman, S. Preferntial effects of caffeine on limbic and cortical dopamine systems. Biological Psychiatry. 1988; 23: p. 761–768.CrossRefGoogle Scholar
9.Ferré, S, Fuxe, K, von Euler, G, Johansson, B, Fredholm, B. Adenosine-dopamine interactions in the brain. Neuroscience. 1992; 51: p. 501–512.CrossRefGoogle ScholarPubMed
10.Cunha, R, Ferre, S, Vaugeois, J, Chen, J. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des. 2008; 14(15): p. 1512–1524.CrossRefGoogle ScholarPubMed
11.Fisone, G, Borgkvist, A, Usiello, A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004; 61: p. 857–872.CrossRefGoogle ScholarPubMed
12.Lucas, P, Plckar, D, J K, , Rapaport, M, Pato, C, Hommer, D. Effects of the acute administration of caffeine in patients with schizophrenia. Biological Psychiatry. 1990 July; 28(1): p. 35–40.CrossRefGoogle ScholarPubMed
13.Zaslove, M, Russell, R, Ross, E. Effect of Caffeine Intake on Psychotic In-patients. British Journal of Psychiatry. 1991; 159: p. 565–567.CrossRefGoogle ScholarPubMed
14.Caykoylu, A, Ekinci, O, Kuloglu, M. Improvement from treatment-resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul; 32(5): p. 1349–50.CrossRefGoogle ScholarPubMed
15.Hedges, D, Woon, F, Hoopes, S. Caffeine-induced psychosis. CNS Spectr. 2009 Mar; 14(3): p. 127–129.CrossRefGoogle ScholarPubMed
16.de Leon, J. Atypical Antipsychotic Dosing: The effect of Smoking and Caffeine. Psychiatric Services. 2004 May; 55(5): p. 491–493.CrossRefGoogle ScholarPubMed
17.Rasmussen, B, Brix, T, Kyvik, K, Brøsen, K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics. 2002; 12(6): p. 473–8.CrossRefGoogle ScholarPubMed
18.Regier, D, Farmer, M, Rae, D, Locke, B, Keith, S, Judd, L, et al.Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990 Nov; 264(19): p. 2511–8.CrossRefGoogle ScholarPubMed
19.Hermens, D, Lubman, D, Ward, P, Naismith, S, Hickie, I. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust. 2009 Feb; 190((4 Suppl)): p. S22–5.CrossRefGoogle Scholar
20.Semple, D, McIntosh, A, Lawrie, S. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005 Mar; 19(2): p. 187–194.CrossRefGoogle ScholarPubMed
21.Hall, W, Degenhardt, L. Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust N Z J Psychiatry. 2000 Feb; 34(1): p. 26–34.CrossRefGoogle ScholarPubMed
22.Zammit, S, Moore, T, Lingford-Hughes, A, Barnes, T, Jones, P, Burke, M, et al.Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008 Nov; 193(5): p. 357–63.CrossRefGoogle ScholarPubMed
23.Henquet, C, Di Forti, M, Morrison, P, Kuepper, R, Murray, R. Gene-environment interplay between cannabis and psychosis. Schizophr Bull. 2008 Nov; 34(6): p. 1111–21.CrossRefGoogle ScholarPubMed
24.Sewell, R, Ranganathan, M, D'Souza, D. Cannabinoids and psychosis. Int Rev Psychiatry. 2009 Apr; 21(2): p. 152–62.CrossRefGoogle ScholarPubMed
25.Nehlig, A. Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci Biobehav Rev. 1999 Mar; 23(4): p. 563–576.CrossRefGoogle ScholarPubMed
26.Nehlig, A, Boyet, S. ose-response study of caffeine effects on cerebral functional activity with a specific focus on dependence. Brain Res. 2000 Mar; 858(1): p. 71–77.CrossRefGoogle ScholarPubMed